Basem M. William, MD, MRCP
Basem M. William, MD, MRCP, Director of the T-Cell Lymphoma Program and Cutaneous Lymphoma Multidisciplinary Clinic at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, commented on the newly reported findings with lisocabtagene maraleucel for The ASCO Post.
“The TRANSCEND study shows very promising data for lisocabtagene maraleucel that may represent the ‘best of both worlds’ when it comes to [chimeric antigen receptor (CAR)] T-cell therapy: a high objective response rate (73%) and reliable manufacturing (24-day vein-to-vein time), as we see also with axicabtagene ciloleucel, and low rates of cytokine-release syndrome and neurotoxicity, as we see with tisagenlecleucel,” Dr. William said.
The objective response rate and complete response rates are reported to be 72% and 51%, respectively, with axicabtagene ciloleucel and 50% and 32%, respectively, with tisagenlecleucel.
“Axicabtagene ciloleucel and tisagenlecleucel have produced ‘real-world data’ as well as clinical trial data. I think [lisocabtagene maraleucel] now has to generate such data as well to earn its position in the CAR T-cell market,” he said.
DISCLOSURE: Dr. William reported no conflicts of interest.
[Data from the TRANSCEND study] support the use of lisocabtagene maraleucel in a broad range of patients and in the outpatient setting.— Jeremy Abramson, MD
Tweet this quote
Another CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be poised to enter...